-da-Silva. Gi␣3 protein-coupled dopamine D3 receptor-mediated inhibition of renal NHE3 activity in SHR proximal tubular cells is a PLC-PKC-mediated event. Am J Physiol Renal Physiol 287: F1059 -F1066, 2004. First published July 20, 2004 doi:10.1152/ajprenal.00139.2004.-This study evaluated the transduction pathway associated with type 3 Na ϩ /H ϩ exchanger (NHE3) activity-induced inhibition during dopamine D3 receptor activation in immortalized renal proximal tubular epithelial cells from the spontaneously hypertensive rat. The dopamine D3 receptor agonist 7-OH-DPAT decreased NHE3 activity, which was prevented by the D2-like receptor antagonist S-sulpiride, pertussis toxin (PTX; overnight treatment), and the PKC inhibitor chelerythrine, but not by cholera toxin (overnight treatment), the MAPK inhibitor PD-098059, or the p38 inhibitor SB-203580. The PKA inhibitor H-89 abolished the inhibitory effects of forskolin on NHE3 activity, but not that of 7-OH-DPAT. The phospholipase C (PLC) inhibitor U-73122 prevented the inhibitory effects of 7-OH-DPAT, whereas PDBu and 7-OH-DPAT increased PLC activity and reduced NHE3 activity; downregulation of PKC abolished the inhibitory effects of both PDBu and 7-OH-DPAT on NHE activity. The inhibition of NHE3 activity by GTP␥S and the prevention of the effect of 7-OH-DPAT by PTX suggest an involvement of a G i/o protein coupled to the dopamine D3 receptor. Indeed, the 7-OH-DPAT-induced decrease in NHE3 activity was abolished in cells treated overnight with the anti-Gi␣3 antibody, but not in cells treated with antibodies against Gq/11, Gs␣, G␤, and Gi␣1,2 proteins. The calcium ionophore A-23187 and the Ca 2ϩ -ATPase inhibitor thapsigargin increased intracellular Ca 2ϩ but did not affect NHE3 activity. However, the inhibitory effects of PDBu and 7-OH-DPAT on NHE3 activity were completely abolished by A-23287 and thapsigargin. It is concluded that inhibition of NHE3 activity by dopamine D3 receptors coupled to Gi␣3 proteins is a PLC-PKC-mediated event, modulated by intracellular Ca 2ϩ . , and D 4 ), which are differentially expressed along the nephron (12, 33). The autocrine/paracrine function of dopamine, manifested by tubular rather than by hemodynamic mechanisms, becomes most evident during extracellular fluid volume expansion (25). This renal autocrine/paracrine function is lost in essential hypertension and in some animal models of genetic hypertension (4, 22-24, 28, 45, 56). Furthermore, disruption of the D 1 or D 3 receptor produces hypertension in mice (1, 5). In some humans with essential hypertension, renal dopamine production in response to sodium loading is impaired and may contribute to the hypertension (48). However, urinary dopamine is higher in young adults with hypertension than normotensive controls, indicating abnormality at the receptor or postreceptor levels (44). The molecular basis for the dopaminergic dysfunction in hypertension is not known but may involve an abnormal posttranslational modification of the dopamine receptor. There may be a primary defect in D 1 -like receptors and an altered signaling system in the proximal tubules and thick ascending limbs of Henle that lead to reduced dopamine-mediated effects on renal sodium excretion in hypertension (25, 45). There are currently eight cloned mammalian Na/H exchangers (NHEs), which differ from each other in tissue distribution, sensitivity to NHE inhibitors, localization, and function (19, 21, 39) . All isoforms are expressed in renal tissues, with the exception of NHE5, whereas NHE type 3 (NHE3) predominates in the apical membrane of rat renal proximal tubules (7, 27) and is largely responsible for sodium and hydrogen ion transport in this nephron segment. NHE3 activity and membrane recycling are acutely regulated by phosphorylation/dephosphorylation processes that involve protein kinase A (PKA) and/or protein kinase C (PKC) (3, 29, 37, 52, 53, 57, 58) . NHE3 can also be regulated by G proteins independently of cytosolic second messengers (2, 9, 11). We recently reported that D 1 agonists decrease NHE3 activity by classic stimulation of adenylyl cyclase (AC) and PKA via G S ␣ proteins in rat kidney cells (42); by contrast, the D 1 -mediated inhibition of NHE3 in opossum kidney cells involves both the AC-PKA and PLC-PKC pathways (15).
with essential hypertension, renal dopamine production in response to sodium loading is impaired and may contribute to the hypertension (48) . However, urinary dopamine is higher in young adults with hypertension than normotensive controls, indicating abnormality at the receptor or postreceptor levels (44) . The molecular basis for the dopaminergic dysfunction in hypertension is not known but may involve an abnormal posttranslational modification of the dopamine receptor. There may be a primary defect in D 1 -like receptors and an altered signaling system in the proximal tubules and thick ascending limbs of Henle that lead to reduced dopamine-mediated effects on renal sodium excretion in hypertension (25, 45) .
There are currently eight cloned mammalian Na/H exchangers (NHEs), which differ from each other in tissue distribution, sensitivity to NHE inhibitors, localization, and function (19, 21, 39) . All isoforms are expressed in renal tissues, with the exception of NHE5, whereas NHE type 3 (NHE3) predominates in the apical membrane of rat renal proximal tubules (7, 27) and is largely responsible for sodium and hydrogen ion transport in this nephron segment. NHE3 activity and membrane recycling are acutely regulated by phosphorylation/dephosphorylation processes that involve protein kinase A (PKA) and/or protein kinase C (PKC) (3, 29, 37, 52, 53, 57, 58) . NHE3 can also be regulated by G proteins independently of cytosolic second messengers (2, 9, 11) . We recently reported that D 1 agonists decrease NHE3 activity by classic stimulation of adenylyl cyclase (AC) and PKA via G S ␣ proteins in rat kidney cells (42) ; by contrast, the D 1 -mediated inhibition of NHE3 in opossum kidney cells involves both the AC-PKA and PLC-PKC pathways (15) .
In the spontaneously hypertensive rat (SHR), despite normal renal production of dopamine and receptor density, there is defective transduction of the D 1 receptor signal in renal proximal tubules. This coupling defect is genetic (precedes the onset of hypertension and cosegregates with the hypertensive phenotype), is receptor specific (not shared by other humoral agents), and is organ and nephron segment selective (occurs in proximal tubules but not in cortical collecting ducts or the brain striatum) (13, 25, 28, 41) . A consequence of the defective dopamine receptor/PKA/PKC coupling in the SHR is a decreased ability of D 1 -like receptor agonists to inhibit NHE3 activity (1, 22, 25, 55) . However, we have recently reported that stimulation of dopamine D 3 receptors inhibits NHE3 activity in immortalized and freshly isolated renal tubules from the SHR (43) . In line with this view is the recent showing that D 3 dopamine receptor activation increased the glomerular filtration rate (GFR), urinary volume, and sodium excretion in adult SHR and Wistar-Kyoto rats (34) . This is of particular relevance in the SHR, where a defective D 1 receptor signal transduction has been well characterized (23, 25, 26) and may correspond to an attempt to overcome the deficient dopaminemediated natriuresis in genetic hypertension. The present study was carried out to evaluate the signaling events of dopamine D 3 receptor-mediated inhibition of NHE activity in immortalized renal proximal tubular cells from the SHR.
METHODS
Cell culture. Immortalized renal proximal tubular epithelial cells from 4-to 8-wk-old SHR animals (54) were maintained in a humidified atmosphere of 5% CO 2-95% air at 37°C. SHR cells were grown in Dulbecco's modified Eagle's medium nutrient mixture F-12-Ham's (Sigma, St. Louis, MO) supplemented with 100 U/ml penicillin G, 0.25 g/ml amphotericin B, 100 g/ml streptomycin (Sigma), 4 g/ml dexamethasone (Sigma), 5 g/ml transferrin (Sigma), 5 g/ml insulin (Sigma), 5 ng/ml selenium (Sigma), 10 ng/ml epidermal growth factor (Sigma), 5% fetal bovine serum (Sigma), and 25 mM HEPES (Sigma). For subculturing, the cells were dissociated with 0.10% trypsin-EDTA, split 1:4, and subcultured in Costar plates with 21-cm 2 growth areas (Costar, Badhoevedorp, The Netherlands). For measurements of intracellular pH (pHi), PLC activity, and intracellular calcium, cells were grown in 96-well plates (Costar) or in polycarbonate filter supports (internal diameter 12 mm, Transwell, Costar), 6-well plates (Costar) and in coverslips, respectively. The cell medium was changed every 2 days, and the cells reached confluence after 3-5 days of incubation. For 24 h before each experiment, the cells were maintained in fetal bovine serum-free medium. Experiments were generally performed 1-2 days after cells reached confluence and 4 -5 days after the initial seeding; each cm 2 contained ϳ50 g of cell protein.
Na ϩ /H ϩ exchanger activity. NHE activity was assayed as the initial rate of pHi recovery (5 min) after an acid load imposed by 20 mM NH4Cl (5 min), followed by removal of Na ϩ (5 min) from the Krebs' modified buffer solution (in mM: 140 NaCl, 5.4 KCl, 2.8 CaCl 2, 1.2 MgSO4, 0.3 NaH2PO4, 0.3 KH2PO4, 10 HEPES, 5 glucose, pH 7.4, adjusted with Tris base), in the absence of CO2/HCO3 (17) . In these experiments, NaCl was replaced by an equimolar concentration of tetramethylammonium chloride (TMA). Test compounds were added to the extracellular fluid during the acidification and Na ϩ -dependent pHi recovery periods. Intracellular pH measurements were performed in SHR cells cultured in polycarbonate filter supports or in 96-well plates (18) . After loading the cells with 5 M BCECF-AM at 37°C for 30 min, test compounds were added to the extracellular fluid 25 min before starting the sodium-dependent pH i recovery period. Cells were placed in the sample compartment of a dual-scanning microplate spectrofluorometer (Spectramax Gemini, Molecular Devices, Sunnyvale, CA), and fluorescence was measured every 19 s alternating between 440-and 490-nm excitation at 535-nm emission, with a cutoff filter of 530 nm. The ratio of intracellular BCECF fluorescence at 490 and 440 nm was converted to intracellular pH values by comparison with values from an intracellular calibration (performed for each day of experiment) curve using the nigericin (10 M) and high-K ϩ method (17) . Downregulation studies. Downregulation of classical and new PKCs was performed by overnight exposure to phorbol-12,13-dibutyrate (PDBu; 100 nM), respectively, as previously described (15, 16, 50) .
PLC activity. PLC activity was assayed as previously described (16) . Cells grown in six-well culture clusters were incubated for 25 min at 37°C with test compounds in Hanks' medium. Washing the cells with ice-cold Hanks' medium three times terminated the reaction. Subsequently, the cells were lysed by adding lysis buffer containing (in mM) 20 Tris ⅐ HCl, pH 7.4, 2 EDTA, 2 phenylmethylsulfonyl fluoride, 25 sodium pyrophosphate, 20 sodium fluoride, and 10 g/ml each leupeptin and aprotinin. The lysate was assayed for PLC activity using the Amplex Red phosphatidylcholine-specific PLC assay kit (Molecular Probes, Eugene, OR) and a Spectramax Gemini dual-scanning fluorescence microplate reader (Molecular Devices). In brief, PLC was monitored indirectly using 10-acetyl-3, 7-dihydroxyphenoxazine (Amplex Red reagent), a sensitive fluorogenic probe for H 2O2. Assays were performed in 96-well plates, with 200-l reaction volume. First, PLC converts the phosphatidylcholine (lecithin) substrate to form phosphocholine and diacylglycerol. Then, alkaline phosphatase hydrolyses phosphocholine and choline is oxidized by choline oxidase to betaine and H 2O2. Finally, H2O2 in the presence of horseradish peroxidase reacts with Amplex red reagent in a 1:1 stoichiometry to generate the highly fluorescent product resorufin.
Intracellular calcium measurement. Intracellular calcium was measured as previously described (16) . At day 4 after seeding, the glass coverslips were incubated at 37°C for 60 min with 10 M calciumdependent fluorescent indicator fura 2. Coverslips were then washed twice with prewarmed dye-free modified Krebs buffer [buffer composition (in mmol/l) 140 NaCl, 5.4 KCl, 0.5 CaCl 2, 1.2 MgSO4, 0.3 NaH2PO4, 0.3 KH2PO4, 10 HEPES, 5 glucose, pH 7.4 with Tris base], before initiation of the fluorescence recordings. Cells were mounted diagonally in 1 ϫ 1-cm acrylic fluorometric cuvettes, which were placed in the sample compartment of a FluoroMax-2 spectrofluorometer (Jobin Yvon-SPEX, Edison, NJ). The cuvette volume of 3.0 ml was constantly stirred and perfused at 5.0 ml/min with modified Krebs buffer prewarmed to 37°C. Under these conditions, the cuvette medium was replaced within ϳ150 s. After 5 min, fluorescence was measured every 5 s alternating between 340-and 380-nm excitation (2-nm slit size) at 510-nm emission (5-nm slit size). The ratio of intracellular fura 2 fluorescence at 340 and 380 nm was an index of intracellular calcium. The free Ca 2ϩ concentration ([Ca 2ϩ ]free) was calculated using the equation (20) [
where Kd is the dissociation constant, R is the ratio of each 340 nm/380 nm, Rmin and Rmax are the ratios at saturating and zero Ca 2ϩ concentrations, respectively, and F380, max and F380, min are the maximal and minimal fluorescence intensities at 380 nm at saturating and zero Ca 2ϩ concentration, respectively. Drugs. Chelerythrine chloride, cholera toxin, dibutyryl cAMP, dopamine hydrochloride, forskolin, guanosine 5Ј-O-(3-thiotriphosphate) (GTP␥S), H-89, PD-98059, pertussis toxin, phorbol-12,13-dibutyrate (PDBu), SB-203580, and U-73122 were purchased from Sigma. R-(ϩ)-7-Hydroxy-DPAT (7-OH-DPAT), SKF-83566 hydrochloride, (Ϯ)-SKF-38393 hydrochloride, and S(-)-sulpiride were obtained from Research Biochemicals International. Acetoxymethyl ester of 2Ј,7Ј-bis(carboxyethyl)-5(6)-carboxyfluorescein (BCECF-AM), fura 2, and nigericin were obtained from Molecular Probes. S-3226 3-(54)-N-isopropylidene-2-methyl-acrylamide dihydrochloride was kindly provided by Dr. H. J. Lang (Aventis Pharma Deutschland, Frankfurt am Main, Germany).
Data analysis. Arithmetic means are given with SE or geometric means with 95% confidence values. Statistical analysis was done with a one-way ANOVA followed by the Newman-Keuls test for multiple comparisons. A P value Ͻ0.05 was assumed to denote a significant difference.
RESULTS
NHE activity was assayed as the initial rate of the Na ϩ -dependent pH i recovery, measured after an acid load imposed by 20 mM NH 4 Cl, followed by removal of Na ϩ from the Krebs modified buffer solution, in the absence of CO 2 /HCO 3 . In some experiments, SHR cells were cultured in permeable polycarbonate filters to access the apical NHE activity only. In this type of assay, the pH i recovery was measured in the absence of Na ϩ in the basal cell side. NHE activity in SHR cells was decreased by the selective dopamine D 3 receptor agonist 7-OH-DPAT (100 M) in cells cultured in polycarbonate filters or in plastic clusters ( Fig. 1 and Table 1 ). Furthermore, the basal activity of NHE and the inhibition mediated by 7-OH-DPAT (100 M) in cells cultured in polycarbonate filters (basal 0.00893 Ϯ 0.00067 pH U/s, n ϭ 5; 7-OH-DPAT 0.00573 Ϯ 0.00037 pH U/s, n ϭ 5) were similar to that obtained in cells cultured in plastic dishes (basal 0.00942 Ϯ 0.00033 pH U/s, n ϭ 14; 7-OH-DPAT 0.00654 Ϯ 0.00033 pH U/s, n ϭ 13). The apical NHE activity was also reduced by the selective NHE3 inhibitor S-3226 (1 M; 0.00697 Ϯ 0.00033 pH U/s), a selective inhibitor of NHE3 (47) . As shown in Fig.  1B , the effect of 7-OH-DPAT on apical NHE activity was abolished by the presence of S-3226. This strongly suggests that the NHE3 is the major isoform involved in the response to 7-OH-DPAT. As shown in Next, we evaluated the effects of GTP␥S, a nonhydrolyzable GTP analog, to confirm the involvement of G proteins in the regulation of NHE3. Treatment of SHR cells with increasing concentrations of GTP␥S (Table 1 ) reduced NHE3 activity, in a concentration-dependent manner. Cholera toxin (CTX) and pertussis toxin (PTX) ribosylate the ␣-subunit of the G s and G i/o classes of G proteins, respectively. The effect of 7-OH-DPAT was abolished by overnight treatment of SHR cells with PTX (100 ng/ml), but not with CTX (500 ng/ml) ( Table 1) . These results suggest that dopamine D 3 receptors stimulated by 7-OH-DPAT in SHR cells are coupled to PTX-sensitive G proteins of the G i/o class. To further elucidate the coupling of dopamine D 3 receptors to G proteins, additional studies were performed in cells treated overnight with antibodies raised against rat G s ␣, G q/11 , G i ␣3, G i ␣1,2, or G ␤ proteins. Antibodies were complexed with liposomes to facilitate delivery into the cytosol (15, 16) . As shown in Fig. 2 , the inhibitory effect of 7-OH-DPAT on NHE3 was abolished in cells treated with the anti-G ␣i3 antibody, but not in cells treated with the anti-G s ␣, anti-G q/11 , anti-G i ␣1,2 or anti-G ␤ antibodies.
NHE3 activity is acutely regulated by phosphorylation/ dephosphorylation, a process that may involve PKA and/or PKC and membrane recycling in intact cells (3, 29, 36, 37, 52, 53, 57) . To address these issues, cells were treated with selective antagonists of PKA (H-89) or PKC (chelerythrine). As shown in Fig. 3, H-89 abolished the inhibitory effects of forskolin, an adenylyl cyclase agonist, on NHE3 activity, but not that of 7-OH-DPAT. These suggest that PKA did not participate in the signal transduction pathway of dopamine D 3 receptor activation. To evaluate the contribution of PKC in signal transduction pathway coupled to the dopamine D 3 receptor, the effect of PDBu, an activator of classical and novel PKCs, was examined. Treatment of SHR cells with increasing concentrations of PDBu (10 -3000 nM; Fig. 4A ) reduced the NHE3 activity. As shown in Fig. 4B , chelerythrine (1 M) antagonized the effects of both PDBu (100 nM) and 7-OH-DPAT (100 M). To confirm the involvement of PKC on the inhibition of NHE3 evoked by dopamine D 3 receptor stimulation, complementary studies involving downregulation of PKC were performed. To promote classic and novel PKC downregulation, SHR cells were incubated overnight in the presence of PDBu (100 nM). Under these conditions, PDBu or 7-OH-DPAT was devoid of effect on NHE3 activity (Fig. 4C) . Several studies, including some of our group, demonstrated a critical role of PLC in modulation of Na ϩ -K ϩ -ATPase and NHE3 activity evoked by dopamine receptor stimulation (14, 16, 26, 42, 51) . To evaluate the involvement of PLC in the signal transduction pathway coupled to dopamine D 3 receptormediated inhibition of NHE3, we tested the PLC inhibitor U-73122 (8) on the effect of 7-OH-DPAT. As shown in Fig. 5 , U-73122 (3 M) prevented the inhibitory effects of 7-OH-DPAT on NHE3 activity. As shown in Fig. 6 , 7-OH-DPAT (100 M) and PDBu (100 nM) increased PLC activity in SHR cells, whereas U-73122 (3 M) effectively reduced the PLC activity. The role of PLA 2 -arachidonic acid-20-HETE pathway has been also reported in the signaling subsequent to dopamine receptor stimulation, namely in inhibition of Na ϩ -K ϩ -ATPase in the proximal tubules (40) . The result that arachidonic acid was devoid of an effect (Table 2) in NHE3 activity is compat- ible with the view that metabolites of PLA 2 are not positively coupled to inhibition of NHE3 activity in SHR cells. Other signal transduction pathways that might affect NHE3 activity are related with the MAPK (32, 35, 49) . To evaluate the contribution of MAPK in the dopamine D 3 receptor-induced decrease in NHE3 activity, the MAPK inhibitor PD-098059 and the p38 inhibitor SB-203580 were tested. As shown in Table 2 , the effect of 7-OH-DPAT was not prevented by either PD-098059 or SB-203580.
The activation of dopamine D 3 receptors causes the stimulation of PLC and generation of inositol trisphosphate and diacylglycerol. Diacylglycerol stimulates PKC, which in turn inhibits NHE3 activity. On the other hand, inositol trisphosphate increases in intracellular Ca 2ϩ concentrations. For these reasons, we decided to evaluate the relationships among intracellular Ca 2ϩ , PKC activation, and NHE3 activity following dopamine D 3 receptor stimulation. As shown in Fig. 7A , the calcium ionophore A-23187 did not change NHE3 activity. However, the effects of PDBu and 7-OH-DPAT on NHE3 activity were completely abolished (Fig. 7B) by the A-23187 (3 M), added before (5 min) and during (25 min) the treatment with 7-OH-DPAT and PDBu. The cell-permeable inhibitor of calcium ATPase in the endoplasmic reticulum thapsigargin decreased NHE3 activity only at the highest concentration tested (10 M; Fig. 8A ). Similarly, a concentration of thapsigargin (3 M) that failed to affect NHE3 activity prevented the 7-OH-DPAT-and the PDBu-induced decrease in NHE3 activity (Fig. 8B) Fig. 9 , stimulation of D 3 dopamine receptors by 7-OH-DPAT (100 M) had no effect on [Ca 2ϩ ] i (32.7 Ϯ 0.1 nmol/l; n ϭ 5), whereas both A-23187 (3 M) and thapsigargin (3 M) markedly raised intracellular Ca 2ϩ in SHR cells. The maximal concentration of free Ca 2ϩ obtained for A-23187 (3 M) and thapsigargin (3 M) was 162.9 Ϯ 2.8 nmol/l (n ϭ 4) and 79.3 Ϯ 2.6 nmol/l (n ϭ 3), respectively.
DISCUSSION
We previously reported that stimulation of dopamine D 3 receptors inhibits NHE3 activity in immortalized and freshly isolated renal tubules from the SHR (43) . In the present study, it is demonstrated that in immortalized proximal tubular cells from the SHR, downstream to the G i ␣3-coupled dopamine D 3 receptor, NHE3 inhibition involves the PLC-PKC system. The involvement of PKA on the signal transduction activated by dopamine D 3 receptors was also addressed. Several findings suggest the involvement of PKA in regulation of NHE3 activity (29, 36, 52) . However, selective inhibition of PKA with H-89 prevented the decrease in NHE3 activity by forskolin, but not by 7-OH-DPAT. This suggests that PKA does not participate in the signal transduction pathway following dopamine D 3 receptor activation, although it has a role in cAMP-dependent regulation of NHE3 activity.
Activation of PLC is considered to be one of the cellular signaling events involved in dopamine-mediated natriuresis (26, 51) . In fact, the modulation of Na ϩ -K ϩ ATPase and NHE3 activity by dopamine receptor stimulation has been related to PLC activation (14, 16, 42) . The finding that the PLC inhibitor U-73122 prevented the inhibitory effect of 7-OH-DPAT on NHE3 activity and that dopamine D 3 receptor stimulation significantly increased PLC activity suggests that downstream dopamine D 3 receptor transduction includes G ␣i3 -PLC activation. Because activation of PKC is one of the major consequences of PLC signaling (6, 38) , the effects of PDBu, a direct activator of PKC, and chelerythrine, a PKC inhibitor, were also evaluated. The findings reported here in SHR cells show that PDBu reduced NHE3 activity in a concentration-dependent manner, which was prevented by the PKC inhibitor chelerythrine. Similarly, PKC inhibition by chelerythrine prevented the decrease in NHE3 activity by 7-OH-DPAT. These results suggest the involvement of classic or novel PKCs in the signal transduction pathway following dopamine D 3 receptor activa- tion. This view was confirmed in studies in which downregulation of PKC abolished the inhibitory effects of PDBu and 7-OH-DPAT on NHE3 activity. The involvement of PKC is consistent with previous reports showing that NHE3 activity is acutely regulated by PKC-dependent phosphorylation/dephosphorylation processes (3, 53) . We suggest that a single sequence of events downstream of dopamine D 3 receptor activation with PLC activation prior to PKC activation is involved in the regulation of NHE3 activity in SHR cells. However, PDBu markedly increased PLC activity, possibly as a consequence of the potentiation of PLC signaling by PKC, as has been shown for several receptors including the D 1 receptor (46, 58) .
One consequence of PLC activation is an increase in intracellular Ca 2ϩ . However, the role of Ca 2ϩ in NHE3 regulation is not clear, although there is evidence suggesting that Ca 2ϩ might modulate the activity of NHE3 (31) . Therefore, we evaluated the relationships among Ca 2ϩ , PKC activation, and inhibition of NHE3 activity during dopamine D 3 receptor activation. The findings that A-23187 did not change NHE3 activity and that the decrease in NHE3 activity with thapsigargin was observed only at high concentrations suggest that increases in intracellular Ca 2ϩ may not have a direct role in the regulation of NHE3 activity. It should be underscored, however, that A-23187 and thapsigargin, at concentrations that did not affect NHE3 activity, completely prevented the inhibition of NHE3 activity by 7-OH-DPAT and PDBu. These observations suggest a role of intracellular Ca 2ϩ on a PKC-dependent modulation of NHE3 activity. Cheng et al. (10) reported that the regulation of Na ϩ -K ϩ -ATPase activity by PKC is dependent on the intracellular Ca 2ϩ concentration and that its inhibitory effect on Na ϩ -K ϩ -ATPase is reversed by increases in intracellular Ca 2ϩ . In agreement with this hypothesis, regucalcin, a Ca 2ϩ -binding protein, caused an inhibition of PKC activity in rat renal cortex cytosol, only when Ca 2ϩ is present (30) . The finding that Ca 2ϩ modulates the regulation of NHE3 activity by PKC has an important physiological implication, i.e., PKC-mediated inhibition of NHE3 activity involving PKC activation might occur with no or minor changes in intracellular Ca 2ϩ . By contrast, when PKC activation is accompanied by increases in intracellular Ca 2ϩ changes in NHE3 activity do not occur.
In conclusion, the transduction mechanisms set into motion following the coupling of the dopamine D 3 receptor to G i ␣3 proteins may involve PLC and PKC activation in a single sequence of events that results in inhibition of NHE3 activity. Intracellular Ca 2ϩ appears to have a modulatory role in dopamine D 3 receptor-and PKC-mediated decrease in NHE3 activity in SHR cells.
